Ricolinostat is under clinical development by Regenacy Pharmaceuticals and currently in Phase II for Diabetic Neuropathic Pain. According to GlobalData, Phase II drugs for Diabetic Neuropathic Pain have an 18% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ricolinostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ricolinostat overview
Ricolinostat (ACY-1215) is under development for the treatment of chemotherapy induced peripheral neuropathy, diabetic peripheral neuropathy, diabetic neuropathic pain, relapsed/refractory multiple myeloma, relapsed or refractory non-Hodgkin's lymphoma or Hodgkin's lymphoma, ovarian cancer, fallopian tube cancer, polycystic kidney disease, peritoneal cancer, metastatic breast cancer, Charcot-Marie-Tooth disease type II, pancreatic cancer and relapsed and refractory chronic lymphocytic leukemia (CLL). The drug candidate is administered orally as form of a liquid. It targets histone deacetylase 6 (HDAC6). The drug candidate is developed by using iterative biasing chemistry technology. The drug candidate was in development for the treatment of lung cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, cholangiocarcinoma and metastatic breast cancer.
Regenacy Pharmaceuticals overview
Regenacy Pharmaceuticals a pharmaceutical company which focuses on novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function. Regenacy Pharmaceuticals is headquartered in Waltham, Massachusetts, the US.
For a complete picture of Ricolinostat’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
